You just read:

The Newly Launched IL-17 Inhibitor Cosentyx is Gradually Gaining Momentum in the EU5, While Established Subcutaneous TNF-Alpha Inhibitors Humira and Enbrel Continue to Dominate Biologics Patient Share in Psoriasis

News provided by

Decision Resources Group

Jun 01, 2016, 10:08 ET